News | August 02, 2021
Glenmark signs agreement with SaNOtize to manufacture NONS
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
Sun Pharma has committed Rs. 100 crores towards these initiatives
The study was conducted in patients with mild to moderate COVID-19
Riding COVID-19 wave, Indian vaccine industry set to be Rs. 700 billion strong
174 applications were received for 23 eligible products under Target Segment IV - Other Chemical Synthesis Based KSMs/ Drug Intermediates/APIs.
The medical device Sector in India suffers from a considerable cost of manufacturing disability.
Subscribe To Our Newsletter & Stay Updated
